Imunology and the challenge of transplantation

Advances in Experimental Medicine and Biology

Volumn 741, Issue , 2012, Pages 27-43

  Alonso Arias, Rebeca ^a   López Vázquez, Antonio ^a   López Larrea, Carlos ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MHC CLASS 1 RELATED CHAIN A; MHC CLASS 1 RELATED CHAIN B; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; HLA ANTIGEN; PEPTIDE;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN STRUCTURE; ARTICLE; CHROMOSOME 6; CHRONIC GRAFT REJECTION; CROSS PRESENTATION; GENE MAPPING; GENETIC POLYMORPHISM; HUMAN; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR GENE; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR GENE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; PHYSIOLOGY;

ANTIGEN PRESENTATION; HLA ANTIGENS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, MOLECULAR; ORGAN TRANSPLANTATION; PEPTIDES;

EID: 84859786716     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-2098-9_3     Document Type: Article

References (43)

1. Gibson T, Medawar PB. The fate of skin homografts in man. J Anat 1943; 77:299-3 10.
2. Snell GD, Higgins GF. Alleles at the histocompatibility-2 locus in the mouse as determined by tumor transplantation. Genetics. 1951; 36(3):306-3 10.
3. Dausset J, Nenna A, Brecy H. Presence of a leukoagglutinin in serum of three leukopenic patients. Sang 1953; 24(5):410-417.
4. PayneR. The association of febrile trans fusion reactions with leuko-agglutinins. VoxSang 1957; 2(4):233-24 1.
5. Van Rood J, van Leeuwen, Eernisse JG. Antigens against leukocytes in the serum of pregnant women. Ned Tijdschr Geneeskd 1959; 103: 1928-1931.
6. Patel R, Terasaki PT. Significance of the positive crossmatch test in kidney transplantation. N Engi J Med 1969; 280(14):735-739.
7. Zinkernagel RM, Doherty PC. Restriction of in vitro I-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248:701-702.
8. Campbell RD, Trowsdale J. Map of the human MHC. Immunol Today 1993; 14(7):349-352. (Pubitemid 23198168)
9. Klein J, Sato A. The HLA system. N Engl J Med 2000; 343(1 1):782-786.
10. Marsh SG, Albert ED, Bodmer WF et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens 2010; 75:29 1-455.
11. Strominger JL, Humphreys RE, McCune JM et al. The immunoglobulin-like structure of human histocompatibility antigens. Fed Proc 1976; 35:1177-1182.
12. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996; 14:369-396. (Pubitemid 26130189)
13. BrownjH, JardetzkyTS, GorgaJC etal. Three-dimensional structure ofthehumanclassllhistocompatibility antigen HLA-DRI. Nature 1993; 364:33-39. (Pubitemid 23233452)
14. Bahram S, Bresnahan M, Geraghty DE et al. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994; 9 1:6259-6263. (Pubitemid 24200639)
15. Simpson E, Scott D, JamesE etal. Minor Hantigens: Genesand peptides. Transpl Immunol2002; 10:115-123.
16. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donornatural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2 100. (Pubitemid 34229476)
17. Pamer F, Cresswell P. Mechanisms of MHC class I restricted antigen processing. Ann Rev Immunol 1998; 16:323-358. (Pubitemid 28183368)
18. Rock KL, Goldberg AL. Degradation of cell proteins and generation of MHC class I-presented peptides. Ann Rev Immunol 1999; 17:739-779. (Pubitemid 29241139)
19. Geuze HJ. The role of endosomes and lysosomes in MHC class II functioning. Immunol Today 1998; 19: 282-28 7. (Pubitemid 28300198)
20. Villadangos JA, Ploegh HL. Proteolysis in MHC class II antigen presentation: Who's in charge? Immunity 2000; 12:233-239.
21. Engelhard VH. Structure ofpeptides associated with class land class II MHC molecules. Ann Rev Immunol 1994; 12:181-207. (Pubitemid 24140413)
22. Garcia KC, Teyton L, Wilson IA. Structural basis of T-cell recognition. Ann Rev lmmunol 1999; 17:369-397.
23. Reiser JB, Darnault C, Guimezanes A et al. Crystal structure of a T-cell receptor bound to an allogeneic MHC molecule. Nat Immunol 2000; 1(4):291-297.
24. Luz JG, Huang M, Garcia KC et al. Structural comparison of allogeneic and syngeneic T-cell receptor-peptide-major bistocompatibility complex complexes: A buried alloreactive mutation subtly alters peptide presentation substantially increasing V(beta) interactions. J Exp Med 2002; 195(9):1 175-1186. (Pubitemid 34517143)
25. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nature Reviews Immunol 2007; 7:942-955.
26. Archbold JK, Fly LK, Kjer-Nielsen Let al. T-cell allorecognition and MHC restriction A case of Jekyll and Hyde? Mol Immuno 2008; 45(3):583-598.
27. Afzali B, Lechler RI, Hemandez-Fuentes MP. Allorecognition and the alloresponse: Clinical implications. Tissue Antigens 2007; 69(6):545-556. (Pubitemid 46733686)
28. Suchin FJ, Langmuir PB, Palmer F et al. Quantifying the frequency of alloreactive T-cells in vivo: New answers to an old question. J Immunol 2001; 166:973-98 1. (Pubitemid 32060253)
29. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13:438-444.
30. Boisgerault F, Liu Y, Anosova N et al. Differential roles of direct and indirect allorecognition pathways in the rejection of skin and comeal transplants. Transplantation 2009; 87:16-23.
31. Benichou G, Thomson AW. Direct versus indirect allorecognition pathways: On the right track. Am J Transplant 2009; 9:655-656.
32. Bevan MJ. High determinants density may explain the phenomenon of alloreactivity. Immunol Today 1984; 5:128-130.
33. Flliott TJ, Fisen HN. Cytotoxic T-lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc Natl Acad Sci USA 1990; 87:5213-5217.
34. Smith PA, Brunmark A, Jackson MR et al. Peptide independent recognition by alloreactive cytotoxic T-lymphocytes (CTL). J Exp Med 1997; 185:1023-1033. (Pubitemid 27136795)
35. Matzinger P, Bevan MJ. Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29:1-5. (Pubitemid 8070904)
36. Weber DA, Terrell NK, Zhang Y et al. Requirement for peptide in alloreactive CD4+ T-cell recognition of class II MHC molecules. J Immunol 1995; 154:5153-5164.
37. Gökmen MR, Lombardi G, LechlerRl. The importance ofthe indirectpathway of allorecognition in clinical transplantation. Cell Opin Immunol 2008; 20:568-574.
38. Weiss MJ, Guenther DA, Mezrich JD etal. The indirect alloresponse impairs the induction but not maintenance of tolerance to MHC class I-disparate allografts. Am J Transplant 2009; 9:105-113.
39. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155(1 ):3 1-41. (Pubitemid 12209811)
40. Gould DS, Auchincloss H Jr. Direct and indirect recognition: The role of MHC antigens in graft rejection. Immunol Today 1999; 20(2):77-82. (Pubitemid 29136632)
41. Bolton FM, Bradley JA, Pettigrew GJ. Indirect allorecognition: Not simple but effective. Transplantation 2008; 85:667-669. (Pubitemid 351398239)
42. Le MA, Goldman M, Abmmouicz D. Multiple pathuays to allogmft rejection. Transplantation 2002; 73:1373-1381.
43. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3:665-673. (Pubitemid 36745238)